Core Insights - Kraig Biocraft Laboratories, Inc. is recognized for its advancements in spider silk technology, featured on the cover of National Geographic's March 2026 issue [1][13] Group 1: Company Achievements - The article highlights Kraig Labs' innovative approach to producing spider silk fibers using genetically enhanced silkworms, emphasizing its cost-efficiency and high quality [2] - Kraig Labs' recombinant spider silk technology has been tested successfully, demonstrating its strength by towing a car and suspending a person from the ceiling with a single 0.35-ounce loop of thread [4] - The recognition by National Geographic marks a significant milestone for Kraig Labs and the biomaterials innovation sector [3] Group 2: Commercialization and Market Potential - The feature discusses the scalability of silkworm cultivation combined with the performance properties of spider silk, indicating growing commercial opportunities for spider silk biomaterials [2] - Kraig Labs is preparing to ramp up production operations to meet the increasing market demand for high-performance, sustainable fiber and fabric solutions [6]

DENVER, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering what may prove to be the defining phase of its multi-decade development arc, as the company accelerates toward commercial-scale production of biodegradable spid ...

DENVER, Feb. 11, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering a new phase of commercial scale-up as it accelerates production to meet growing demand from global brands. Kraig Labs utilizes advanced gene-editing techniques ...

Core Insights - Kraig Biocraft Laboratories, Inc. has completed the acquisition of its third silkworm rearing center, which is a significant step in its production scale-up for recombinant spider silk in 2026 [1][2][4] Group 1: Production Expansion - The new facility allows Kraig Labs to run three simultaneous production cycles, enabling the company to produce over one metric ton of finished spider silk per month [2] - This production scale-up is the result of years of development, optimizing various elements such as facility design, staffing, and operational workflows based on previous production experiences [3] - The newly acquired center is the largest single-site rearing center for Kraig Labs, designed for higher throughput while ensuring operational discipline and biological consistency [4] Group 2: Strategic Positioning - The new rearing center is strategically located to utilize Kraig's recently acquired mulberry fields, which will provide the necessary feedstock for increased silkworm and spider silk production [5] - These mulberry resources are essential for the company's vertically integrated production model, supporting continuous and high-volume operations across all facilities [5] Group 3: Future Outlook - Kraig Labs is in the process of bringing the new rearing center online and expects to commence operations later this quarter [6] - The CEO of Kraig Labs emphasized that this milestone positions the company to achieve commercially scalable and cost-effective spider silk production [7]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed its latest production cycle, yielding over one million BAM-1 Alpha hybrid eggs, which will be released in the upcoming quarter for recombinant spider silk production [1][2]. Production and Technology Advancements - The BAM-1 Alpha line has shown greater uniformity and resiliency throughout the production process, leading to improved throughput, consistency, and reliability for the company's spider silk manufacturing platform [2][3]. - The production capacity increase from BAM-1 Alpha is driving the company's expansion initiatives in Southeast Asia [3]. Strategic Outlook - The company has developed an aggressive production schedule for the next six months based on the successful results from BAM-1 Alpha and is already implementing this plan [4]. - The reliability and robustness of the BAM-1 Alpha line are enabling the company to confidently advance its commercial rollout [4].

Core Insights - Kraig Biocraft Laboratories, Inc. is fulfilling an order for spider silk from a globally recognized performance sports apparel brand as part of a confidential pilot development program [1][2] - The project aims to incorporate next-generation recombinant spider silk into high-performance apparel, targeting a demanding segment of the athletic market [2][5] - The collaboration highlights the growing recognition of spider silk's potential in high-value applications, aligning with the customer's commitment to innovation [6] Company Developments - The company is processing its recombinant spider silk inventory into yarns tailored to the specifications provided by the customer's development team, with delivery expected before the end of the first quarter [4] - This pilot program involves a small, purpose-built quantity of spider silk, serving as a platform to demonstrate the technology's performance capabilities [5] - Kraig Labs' CEO expressed excitement about the collaboration, emphasizing the alignment of innovation between the company and the customer [6] Industry Context - Kraig Biocraft Laboratories is recognized as a leader in genetically engineered spider silk-based fiber technologies, with significant breakthroughs impacting the global textile industry [8]

Core Insights - Kraig Biocraft Laboratories (KBLB) is positioned to capitalize on the growing demand for high-performance spider silk materials, with significant advancements in its production capabilities and commercialization efforts [1][8][12] Production and Technology Advancements - The 2025 production program will feature the large-scale deployment of the BAM-1 Alpha recombinant silk platform, which is expected to attract interest from luxury brands, defense contractors, and biomedical firms [2][4] - The BAM-1 Alpha platform enhances production efficiency by utilizing genetically engineered silkworms, addressing the challenges of traditional spider farming [3][12] - Recent developments include a 20-30% production increase due to selective breeding updates and the completion of a parallel two-facility cycle, which enhances silk quality and volume [6][10] Market Positioning and Strategic Timing - Kraig Labs is on track to deliver initial quantities of recombinant spider silk fibers to partners before year-end, targeting performance textile, defense, and luxury markets [5][11] - The global technical textiles market is projected to reach $200 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%, providing a favorable environment for KBLB's commercialization efforts [8] - The company's strategic momentum heading into 2026 is bolstered by its ability to meet year-end supply availability for potential customers in luxury apparel and specialty materials [9][11] Supply Chain and Scalability - Kraig Labs has strengthened its supply chains with the establishment of a new diapausing system and a Cambodian operations license, facilitating potential deliveries to European luxury partners [7] - The hybridized silkworm technology has demonstrated repeatable scalability, crucial for consistent supply and commercial delivery of spider silk materials [7][12] - If production remains on schedule, KBLB could enter 2026 with tangible proof of scalability, marking a significant inflection point for the company and its technology [13]

Core Insights - Kraig Biocraft Laboratories, Inc. has significantly increased the production throughput of its recombinant spider silk production platform, marking a major advancement in spider silk technology [1][6]. Company Developments - The increase in production is attributed to the successful selective breeding of parental strains for hybrid silkworms, which form the basis of the recombinant spider silk production system [2][3]. - The first successful hybrid, BAM-1, demonstrated hybrid vigor, leading to increased cocoon shell weight and robustness, which are critical for silk output [2][4]. - The new advanced hybrid, BAM-1 Alpha, has shown a measurable hybrid vigor increase of 22%, representing over a 245% improvement compared to the original BAM-1 [4][5]. Production and Commercialization - The BAM-1 Alpha hybrid is expected to be the primary production strain moving forward, producing larger cocoons and more silk, which will lower production costs [5][6]. - Kraig Labs plans to leverage its multi-facility production infrastructure to integrate BAM-1 Alpha into ongoing manufacturing, supporting its vision of delivering high-performance spider silk fibers for various applications [6][7]. Industry Position - Kraig Labs continues to lead in spider silk research and development, focusing on large-scale commercialization of spider silk technologies [5][7]. - The company's advancements in spider silk technology have significant implications for the global textile industry, with potential applications in performance textiles, defense, medical, and industrial markets [6][10].

Core Insights - Kraig Biocraft Laboratories, Inc. is expanding its recombinant spider silk production by adding a third production facility to meet growing market demand [1][5]. Company Expansion - Over the past 18 months, the company has opened two rearing centers and is now in the process of establishing a third center to further increase production capacity [2]. - The new facility will be located in a leading silk production region, allowing the company to utilize an experienced workforce and robust infrastructure [3]. Production Strategy - The multi-facility strategy aims to support continuous production and build redundancies into the production chain, enhancing resilience to meet current demand [4]. - The CEO of Kraig Labs emphasized the goal of increasing production capacity while ensuring operational resilience [5].

Core Insights - Kraig Biocraft Laboratories, Inc. is pursuing the acquisition of an additional silkworm rearing center as part of its multi-facility expansion strategy to enhance the production of recombinant spider silk [1][3] Group 1: Company Developments - The company has achieved significant production growth and operational advancements over the last 18 months, particularly under the leadership of Dr. Nirmal Kumar, a leading expert in sericulture [2][4] - Kraig Labs relocated its headquarters to Asia's traditional silk-producing regions, resulting in record production volumes and streamlined processes [2][3] - The company aims to create a production network designed for continuous rearing cycles, greater reliability, and significant capacity increases to meet rising global demand [3][5] Group 2: Leadership and Strategy - Dr. Kumar's expertise is crucial for guiding the buildout and integration of the new facility, ensuring consistency and efficiency in large-scale operations [4] - The company's expansion efforts are aligned with its long-term vision to supply affordable, high-quality spider silk as a sustainable material solution [5]